Download as pdf or txt
Download as pdf or txt
You are on page 1of 4

Issues in Emerging Health Technologies

Radiofrequency Neurotomy for


Lumbar Pain
Issue 83 • May 2006

from two levels, medial branch RFN must typically be


Summary
performed at several spinal levels, either unilaterally
 Chronic lumbar (lower back) pain, which affects or bilaterally.
many Canadians, imposes a large economic
burden.
 Symptoms may occur in the vertebral facet joints
of 15% to 40% of patients with lower back pain.
 Medial branch radiofrequency neurotomy is a
minimally invasive outpatient procedure that
reduces pain by interrupting the nerve supply to
painful facet joints.
 Four systematic reviews of this procedure offer
disparate conclusions.
 One small well designed observational study has
shown positive results, but no equally rigorous
randomized controlled trial has been conducted.
Source: US National Institute of Arthritis and
Musculoskeletal and Skin Diseases
The Technology
Regulatory Status
Radiofrequency neurotomy (RFN) is known by many
names, including percutaneous RF facet denervation, Medial branch RFN is a medical procedure, and is not
percutaneous facet coagulation, percutaneous RFN, RF subject to Health Canada regulatory approval.
facet rhizotomy, and RF articular rhizolysis.1 It is a min-
imally invasive, interventional procedure used to treat
chronic spinal pain of facet joint origin. The facet or Patient Group
zygapophyseal joints2 are bilateral structures that link
The economic burden associated with chronic back
each vertebra to its neighbours. Lumbar facet joints
pain is high, and may be comparable to that due to
receive their nerve supply from the medial branches
depression, diabetes, and other common disorders.4 A
of the dorsal rami of the spinal nerves, each facet joint
survey of Canadians aged >12 years (n=118,533) esti-
being innervated by the branch specific to its own
mated that the prevalence of chronic back pain (pain
vertebral level and the branch from the level above.3
for >6 months) during the previous 12 months was
9%, with 19% of respondents reporting pain that was
In medial branch RFN, an insulated electrode with an
severe, 55% moderate, and 26% mild.5 A second
exposed tip is percutaneously introduced into the
Canadian study (n=13,756) identified persistent back
spinal area, and under X-ray fluoroscopic guidance, it
problems as the most common chronic problem
is positioned parallel to the nerve supplying a painful
among those <60 years old, and the third most com-
facet joint. Once positioning has been confirmed, a
mon in those >60 years old; prevalence was estimated
current is passed through the electrode. The resultant
at 15% to 18%.6 Canadian data are unavailable, but
heat destroys adjacent tissue, including the target
studies from the US and Australia indicate that in 15%
nerve, thereby interrupting the transmission of pain
to 40% of patients, chronic back pain may be
signals. Because lumbar facet joints are innervated
attributable to the lumbar facet joints.7,8

The Canadian Agency for Drugs and Technologies in Health (CADTH) is funded by Canadian federal, provincial and territorial governments. (www.cadth.ca)
The only valid and reliable diagnostic test for facet In a small, well designed observational study (n=15),
joint pain is fluoroscopically guided, controlled Dreyfuss et al. used meticulous techniques, including
diagnostic medial branch blocks, or intra-articular controlled diagnostic blocks, and they achieved signifi-
facet joint blocks.2,7,9-12 Patients who are unresponsive cant, sustained reductions in lumbar facet pain.8 In
to conservative therapy and who have positive pain contrast, a RCT designed to reflect common clinical
relief from controlled diagnostic blocks may be practice, including reliance on single diagnostic blocks,
suitable for medial branch RFN. found that medial branch RFN offered no benefit28
(Table 1).
Current Practice
Adverse Effects
Conservative treatments for chronic lumbar pain
include exercise, oral medications, physical therapy, Possible adverse effects (AEs) of medial branch RFN
spinal manipulation, and behavioural therapy. Most include painful cutaneous dysesthesias, neuritis or
have, at best, modest efficacy.13,14 Interventional thera- neurogenic inflammation pain, anesthesia dolorosa,
pies for facet joint pain include intra-articular facet cutaneous hyperesthesia, pneumothorax, and deaf-
joint injections, medial branch nerve blocks, and medi- ferentation pain.11,12 AEs reported in two studies23,28
al branch RFN.11,12 No accurate utilization data are avail- included treatment-related pain, transient neuro-
able for these procedures. However, the use of medial pathic pain, transient leg pain, dysesthesia, and
branch RFN is relatively uncommon in Canada (Dr. D. subjective leg weakness; the other studies reported
Vincent, Victoria, BC: personal communication, 2006 no AEs. One centre performing lumbar medial branch
Mar 02). RFN estimated the incidence of minor AEs at 1% per
lesion site.29
The Evidence
Administration and Cost
Four systematic reviews (SRs) address the efficacy of
medial branch RFN for lumbar facet joint pain.15-18 Historically, medial branch RFN was a neurosurgical
Two15,17 include only randomized controlled trials procedure, but currently, anesthetists and other physi-
(RCTs), while the others16,18 include RCTs and observa- cians specializing in pain medicine perform it most
tional studies. The SRs reach divergent conclusions: often.9 The time required depends on the number of
• Geurts et al.15 found moderate evidence that the levels to be treated, but estimates range from 20 min-
procedure is more effective than placebo. utes (most likely) to five hours.30 Local anesthesia is
• Manchikanti et al.16 found strong evidence that generally used, although general anesthesia may be
the procedure offers short- and long-term pain preferred in some centres.23 The procedure can be
relief. repeated at three-month intervals if >50% pain relief
• Niemesto et al.17 found conflicting evidence on the is obtained for 10 to 12 weeks post-RFN.11,12
short-term effect.
• Boswell et al.18 found moderate to strong evidence Payment may come from provincial health plans or
in favour of efficacy. third-party payers such as workers’ compensation
boards. No cost-effectiveness evaluations were locat-
The SRs include four relevant RCTs19-22 and six observa- ed, and little costing data are available.11,12 A 2001
tional studies.8,13,23-26 Most of the included studies relied Canadian review addressing medial branch RFN for
on single diagnostic blocks [which have a false posi- cervical facet joint pain estimated the procedural cost
tive rate of 27% (95% CI: 22% to 32%) in the lumbar at C$401, excluding physician fees, the cost of diag-
region],7 rather than controlled diagnostic blocks in nostic blocks, and overhead costs (e.g., RF neurotomy
the selected patients. As a result, many enrolled needles, RF generator, fluoroscopy equipment).31 Van
patients may not have had facet joint pain. Wijk et al. reported total actual treatment-related
Consequently, experts such as Hooten et al. have costs for medial branch RFN at US$285, but details
argued that the results of several RCTs19,20,22 are about the cost calculations are lacking.28
invalid.27 This criticism may be applied to all the
studies cited in this bulletin, with the exception of
the Dreyfuss et al. study.8

The Canadian Agency for Drugs and Technologies in Health (CADTH) is funded by Canadian federal, provincial and territorial governments. (www.cadth.ca)
e 1:: Dreyfuss et al. and Van Wijk et al. studies
Table

Authorss and
d Studyy Treatmentt and
d Outcome
e Measuress Results
Comparator
Dreyfuss et al.8 Texas and RFN coagulation of at 1.5, 3, 6, and 12 months: VAS all but lifting tasks and
Australia; prospective audit nerve for 8 to 10 mm for pain; McGill Pain push-pull tasks improved
with 12 months follow-up; (90 seconds @85C); Questionnaire; Roland-Morris significantly; 60% had 90%
n=15; funder was no control group Inventory; NASS Treatment pain relief; 87% had 60%
International Spinal Expectations; isometric push pain relief; scores not
Injection Society and pull, lift tasks, dynamic floor significantly different
to waist lift, isometric above throughout 12-month
shoulder lift; electromyography follow-up
of L2 to L5 multifidus bands
van Wijk et al.28 the treatment group primary: number of successes at primary: number of
Netherlands; multicentre, (n=40): RFN of medial 3 months; secondary: GPE and successes in treatment
randomized, double-blind, branch of dorsal SF-36 group 11 (27.5%) versus 12
sham treatment controlled ramus (60 seconds (29.3%) in control group
trial; n=81; funder was @80C); control group (p=0.86); secondary: only
Dutch Health Insurance (n=41): identical GPE showed significant
Council & Pain Expertise procedure but no RFN difference in favour of
Center Nijmegen treatment group

GPE=global perceived effect; NASS=North American Spine Society; RFN=radiofrequency neurotomy; SF-36=Short Form 36;
VAS=visual analogue scale.

research inconclusive. The most rigorous assessment


Concurrent Development
to date suggests that meticulous attention to diagno-
While there are some practitioners who advocate the sis and treatment may generate positive results,8 but
use of pulsed rather than continuous RF current, this this was extracted from a small observational study,
is a modification of the existing technique.32 One and equally rigorous RCTs have yet to be conducted.
study that was identified recommends intra-articular
(in the joint) RFN rather than medial branch RFN.21 Medial branch RFN is a specialized procedure.
Physicians must place an electrode, depending on its
Rate of Technology Diffusion size, within a millimetre of the target nerve to suc-
cessfully interrupt the nerve supply to the facet joint.
The diffusion of medial branch RFN in Canada is The contrast between the study results of Dreyfuss et
unknown. Demand may increase because of its per- al.8 and Van Wijk et al.28 may highlight the importance
ceived success compared with many conservative of training, and the need for practice guidelines
therapies, and because of the social and personal related to medial branch RFN.
costs of unresolved chronic back pain. The limited
number of physicians practising interventional References
pain management techniques is likely to restrict
1. Cigna healthcare coverage position: radiofrequency
availability.
ablation for chronic spinal pain. Atlanta: CIGNA; 2005.
Available:
http://www.cigna.com/health/provider/medical/pro-
Implementation Issues cedural/coverage_positions/medical/mm_0144_cover-
agepositioncriteria_radiofrequency_ablation_for_chro
Almost 30 years have passed since the first reports nic_spinal_pain.pdf.
about medial branch RFN were published, yet the pro-
2. Manchikanti L. Curr Rev Pain 1999;3(5):348-58
cedure has not gained uptake, and remains an emerg-
3. Lumbar radiofrequency neurotomy for chronic
ing technology.17 Some studies suggest that medial zygapophysialJoint pain: a pilot study using dual medial
branch RFN is efficacious, but procedural and other branch blocks. I S I S Sci Newsl 1999;3(2). Available:
methodological shortcomings render much of this http://www.spinalinjection.com/a/newsltrs/Feb1999.pdf.

The Canadian Agency for Drugs and Technologies in Health (CADTH) is funded by Canadian federal, provincial and territorial governments. (www.cadth.ca)
4. Maetzel A, et al. Best Pract Res Clin Rheumatol 28. van Wijk RM, et al. Clin J Pain 2005;21(4):335-44
2002;16(1):23-30 29. Kornick C, et al. Spine 2004;29(12):1352-4
5. Currie SR, et al. Pain 2004;107(1-2):54-60 30. Curatolo M, et al. Spine 2005;30(2):263-5
6. Rapoport J, et al. Chronic Dis Can 2004;25(1):13-21. 31. Bassett K, et al. Percutaneous radio-frequency neuro-
Available: http://www.phac-aspc.gc.ca/publicat/cdic- tomy treatment of chronic cervical pain following
mcc/25-1/c_e.html. whiplash injury:reviewing evidence and needs.
7. Manchikanti L, et al. BMC Musculoskelet Disord Vancouver: BC Office of Health Technology
2004;5:15. Available: Assessment; 2001. Available:
http://www.biomedcentral.com/1471-2474/5/15. http://www.chspr.ubc.ca/bcohta/pdf/bco01-
8. Dreyfuss P, et al. Spine 2000;25(10):1270-7 05T_PRFN.pdf.
9. Lord SM, et al. Best Pract Res Clin Anaesthesiol 32. Mikeladze G, et al. Spine J 2003;3(5):360-2
2002;16(4):597-617
10. Slipman CW, et al. Spine J 2003;3(4):310-6
11. Manchikanti L, et al. Pain Physician 2003;6(1):3-81.
Available:
http://www.asipp.org/documents/Guidelines%20200
3.pdf.
12. Boswell MV, et al. Pain Physician 2005;8(1):1-47 Cite as: Murtagh J, Foerster V. Radiofrequency neurotomy
for lumber pain [Issues in emerging health technologies
13. Vad VB, et al. Pain Physician 2003;6(3):307-12
issue 83]. Ottawa: Canadian Agency for Drugs and
14. Bogduk N. Med J Aust 2004;180(2):79-83. Available: Technologies in Health; 2006.
http://www.mja.com.au/public/issues/180_02_190104
***********************
/bog10461_fm.pdf.
CADTH appreciates comments from its reviewers.
15. Geurts JW, et al. Reg Anesth Pain Med 2001;26(5):394-
400 Reviewers: W. Mark Erwin, DC PhD, Toronto Western
16. Manchikanti L, et al. Pain Physician 2002;5(4):405-18. Hospital, Toronto ON; Daniel Denis Vincent, MD FRCPC
Available: ABDA, Vancouver Island Health Authority, Vancouver BC.
http://www.painphysicianjournal.com/2002/octo-
ber/2002;5;405-418.pdf. This report and the French version entitled La neurotomie
par radiofréquence dans le traitement des lombalgies
17. Niemisto L, et al. Cochrane Database Syst Rev are available on CADTH’s web site.
2005;(4):CD004058
18. Boswell MV, et al. Pain Physician 2005;8(1):101-14. Production of this report is made possible by financial con-
Available: tributions from Health Canada and the governments of
http://www.painphysicianjournal.com/2005/jan- Alberta, British Columbia, Manitoba, New Brunswick,
uary/2005;8;101-114.pdf. Newfoundland and Labrador, Northwest Territories, Nova
19. Gallagher J, et al. Pain Clinic 1994;7(3):193-8 Scotia, Nunavut, Ontario, Prince Edward Island,
Saskatchewan, and Yukon. The Canadian Agency
20. van Kleef M, et al. Spine 1999;24(18):1937-42
for Drugs and Technologies in Health takes sole
21. Sanders M, et al. Pain Clinic 1999;11(4):329-35 responsibility for the final form and content of this report.
22. Leclaire R, e al. Spine 2001;26(13):1411-6 The views expressed herein do not necessarily
23. Tzaan WC, et al. Can J Neurol Sci 2000;27(2):125-30. represent the views of Health Canada or any provincial or
Available: http://cjns.metapress.com/media/84vpwn- territorial government.
qqyh79l4kmexej/contributions/a/a/q/j/aaqjwkhph8jg ISSN 1488-6324 (online)
6pyg.pdf. ISSN 1488-6316 (print)
PUBLICATIONS MAIL AGREEMENT NO. 40026386
24. North RB, et al. Pain 1994;57(1):77-83 RETURN UNDELIVERABLE CANADIAN ADDRESSES TO
25. Schaerer JP. Int Surg 1978;63(6):53-9 CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH
600-865 CARLING AVENUE
26. Schofferman J, et al. Spine 2004;29(21):2471-3 OTTAWA ON K1S 5S8

27. Hooten WM, et al. Pain Med 2005;6(2):129-38

The Canadian Agency for Drugs and Technologies in Health (CADTH) is funded by Canadian federal, provincial and territorial governments. (www.cadth.ca)

You might also like